Cargando…

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study

INTRODUCTION: To identify the potential factors responsible for the individual variability of dabigatran, we investigated the genetic variations associated with clinical outcomes and pharmacodynamics (PD) in Chinese patients with nonvalvular atrial fibrillation (NVAF). MATERIALS AND METHODS: Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Qian, Xie, Qiufen, Liu, Zhiyan, Mu, Guangyan, Zhang, Hanxu, Zhou, Shuang, Wang, Zhe, Wang, Zining, Zhang, Yatong, Zhao, Zinan, Yuan, Dongdong, Guo, Liping, Wang, Na, Xiang, Jing, Song, Hongtao, Sun, Jianjun, Jiang, Jie, Cui, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714378/ https://www.ncbi.nlm.nih.gov/pubmed/36453946 http://dx.doi.org/10.1002/ctm2.1104

Ejemplares similares

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study
por: Xiang, Qian, et al.
Publicado: (2023)

Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
por: Liu, Zhiyan, et al.
Publicado: (2022)

SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population
por: Xie, Qiufen, et al.
Publicado: (2022)

Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
por: Zhang, Hanxu, et al.
Publicado: (2022)

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population
por: Zhang, Fan, et al.
Publicado: (2022)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
por: Li, Xin, et al.
Publicado: (2020)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
por: Zhao, Nan, et al.
Publicado: (2022)

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report
por: Xiang, Qian, et al.
Publicado: (2020)

Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran
por: Xiong, Yurong, et al.
Publicado: (2020)

Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis
por: Xie, Qiufen, et al.
Publicado: (2022)

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review
por: Milling, Truman J., et al.
Publicado: (2017)

Association between smokeless tobacco use and oral cavity cancer risk in women compared with men: a systematic review and meta-analysis
por: Mu, Guangyan, et al.
Publicado: (2021)

Effectiveness and Safety of Platelet ADP–P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta‐Analysis
por: Liu, Zhiyan, et al.
Publicado: (2019)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation
por: Bachvarova, Velislava, et al.
Publicado: (2017)

Efficacy and Safety of Novel Oral P2Y(12) Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis
por: Sun, Jianjun, et al.
Publicado: (2017)

Ferroptosis of Endothelial Cells in Vascular Diseases
por: Zhang, Hanxu, et al.
Publicado: (2022)

Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
por: Kairov, Gaisa T., et al.
Publicado: (2018)

Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions
por: Ferreira, Jorge, et al.
Publicado: (2012)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Diastolic blood pressure achieved at target systolic blood pressure (120–140 mm Hg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: A real-world study
por: Yu, Yu, et al.
Publicado: (2020)

Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
por: Silva, Vanessa M., et al.
Publicado: (2019)

Management of dabigatran-induced bleeding: expert statement
por: Fries, Dietmar, et al.
Publicado: (2013)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin
por: Watanabe, Tetsuya, et al.
Publicado: (2016)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
por: Li, Xiaoye, et al.
Publicado: (2021)

Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies
por: Wang, Yimin Pearl, et al.
Publicado: (2020)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
por: Koretsune, Yukihiro, et al.
Publicado: (2019)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study
por: Yamamoto, Tomohiko, et al.
Publicado: (2020)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States
por: Jain, Rahul, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_46cb54v3n9aho6fg4jf5h4a8e2